Deuteroncology

Crossfire Oncology

This company develops kinase-targeting inhibitors, degraders and degrader-antibody conjugates to treat cancer patients.

Nuvalent

This biopharmaceutical company develops targeted small molecule kinase inhibitors for patients with genomically defined cancers such as non-small cell lung cancer.

KyDo Therapeutics

This company develops covalent-allosteric small molecule inhibitors for the treatment of challenging cancer variants within the oncology sector.

THERAtRAME

The company develops small molecule inhibitors targeting tRNA epitranscriptomics to treat resistant and immune-refractory cancers for patients with limited therapeutic options.

ProteoValent Therapeutics

This company develops targeted protein degrader therapies for cancer and haematology patients.

iOnctura

The company develops precision small-molecule medicines to treat patients with neglected and hard-to-treat solid tumours and cancers.

TwoStep Therapeutics

The company develops peptide-drug conjugates and targeted therapies for patients with solid tumours.

Mirati Therapeutics

This oncology company develops targeted therapies for patients with cancers driven by genetic mutations, including a marketed inhibitor for non-small cell lung cancer.